The controversial quest to make a ‘contagious’ vaccine

Via Peters

Vaccines in progress 

Renewed interest and funding for the technology popped up around 2016, and today several research groups are developing self-spreading vaccines for animals.

Each of these new vaccines are so-called recombinant viruses. Researchers first identify a protein from the target microbe that serves as an antigen—a substance that triggers immune responses in vaccinated people or animals. Then the researchers select a virus to carry the vaccine and spread it. To do this, researchers capture a few animals from their target population—primates for Ebola, rats for Lassa fever—and isolate a virus that naturally infects those animals. Then they splice in genetic material from the target to create a vaccine.

Each of these vaccines uses a cytomegalovirus, or CMVs, a group that belongs to the herpes family.

CMVs help the researchers overcome several technical challenges. For one, CMVs have large genomes made from double-stranded DNA, which means their genetic code is more stable and can accommodate additional genes from the targeted microbe, says Alec Redwood, a principal research fellow at the University of Western Australia. He conducted self-spreading vaccine research in the early 2000s and is now part of a team developing a CMV-based Lassa fever vaccine.

CMVs also infect a host for life, induce strong immune responses yet do not often cause severe disease. Perhaps most importantly, CMVs are uniquely species-specific; the CMV that spreads among Mastomys natalensis, the rat species that spread Lassa fever, for example, cannot infect any animals other than M. natalensis.

Several small studies have demonstrated that the CMV-based Ebola and bovine tuberculosis vaccines are effective when delivered through traditional injections. Across two trials involving about 50 monkeys, the CMV-based tuberculosis vaccine reduced disease by 68 percent, researchers reported. In a separate study, three out of four monkeys vaccinated with the Ebola vaccine survived direct exposure to Ebola.

Similar experiments with the Lassa virus vaccine are expected to start within the year, according to Redwood. That vaccine will also feature a patent-pending genetic safeguard that allows researchers to control the number of times the vaccine can multiply, thereby limiting its lifetime, Redwood explains.

So far, no one has conducted any field or laboratory studies assessing the impact and safety of these vaccines delivered via the self-spreading mechanism. However, a recent mathematical modelling study reported that if it works as expected, releasing the Lassa fever vaccine could reduce disease transmission among rodents by 95 percent in less than a year.

“You can really see just how powerful the idea could be,” says Nuismer, who was the senior author of the modelling study.

Risks of self-spreading vaccines

Despite the potential benefits, many experts warn that too little is known about zoonotic disease transmission and viral evolution to accurately predict what might happen if a self-spreading vaccine were released into the wild.

“Our understanding of infectious disease dynamics in wildlife remain for the most part too simple to meaningfully predict the outcome of such an intervention,” says Andrew Peters, an associate professor of wildlife health and pathology at Charles Sturt University in Australia and the president of the Wildlife Disease Association.

Bárcena’s view of self-spreading diseases shifted after he saw how previous animal control strategies involving the intentional release of viruses had unforeseen consequences.

For instance, the myxoma virus that had become such a devastating challenge in Europe arose because a man in France intentionally released the virus in 1952 to keep rabbits out of his home garden. In 2018 Spanish researchers started noticing that a myxoma virus was killing wild hares, a species similar to rabbits. Scientists sequenced its genome and concluded that the myxoma virus had mixed with a poxvirus, enabling it to jump species.

“I don’t know if a mathematical model would have said that 70 years later something like this can happen,” says Bárcena who is now a senior scientist at the Centre for Research in Animal Health in Spain.

Filippa Lentzos, a science and international security expert at King’s College London, points out that viruses are genetically unstable and prone to frequent mutations; therefore, a self-spreading vaccine virus could evolve to jump species or cause other unknown consequences in wild and domestic animal populations and, perhaps, even in humans.

Nuismer and Redwood both say it is highly unlikely that a CMV-based vaccine could ever jump species given the virus’s biology. Although the evolutionary factors underlying CMV’s species-specificity are not entirely known, there has never been a documented case in the wild or in a laboratory of a successful cross-species CMV infection.

Another potential risk of self-disseminating vaccines is that ridding wild animals of infectious diseases could disrupt natural population control. The rodents that spread Lassa virus are pests that destroy crops and homes, contaminate stored food and drinking water, and create unsanitary living conditions. If the virus doesn’t affect them anymore, their numbers could skyrocket.

“Say we cure these rodents of Lassa virus and that’s good, that’s great for humanity. Except what if that virus was controlling their population size or something? And then we get a wild expansion of the reservoir rodents,” Nuismer says. “I see this as a much more credible place where we could go wrong … because we could tip the ecology off in a way that would be really unfortunate,” he says.

In addition, there is an emerging understanding that viruses and bacteria exist in complex microbial ecosystems, perhaps keeping each other’s populations in check. The impact of a self-spreading vaccine that wipes out one specific virus might have unknown consequences.

“Dramatically shifting the balance by attempting to eradicate or reduce an endemic virus in nature could risk the emergence of other pathogens which impact both the wildlife species themselves, as well as people and our domestic animals,” says Peters.

To mitigate these risks, Nuismer and Redwood envision a progression of testing setups that moves slowly from lab-controlled trials to large-scale enclosures, perhaps on an island like Sánchez-Vizcaíno and his team did more than 20 years ago.

The long road ahead

Most researchers agree that self-spreading vaccines could never be applied to human populations, because universal informed consent would never be achieved.

“We can’t even get people to take a vaccine in a global pandemic. The idea that you would be able to surreptitiously vaccinate the population with a virus without causing riots is just, you know, it’s stuff of fantasy. It will never be used in humans,” Redwood says.

But even using a self-spreading vaccine among animals faces regulatory and social hurdles.

“What are the political implications of such interventions, which do not recognise and cannot be contained by state or national borders?” Peters asks.

Sandbrink also points out that self-spreading vaccine research poses a biosecurity threat. Developing them and preventing some of their potential consequences involves fine-tuning transmissibility and altering genetic stability, techniques that “uniquely advance certain capabilities applicable to the creation of viruses for pandemics and as biological weapons,” he says.

Scientific and global health communities and funding bodies should consider alternative solutions that provide the same benefit with less risk, Sandbrink urges. For instance, educating people about how to safely interact with wildlife may reduce the chance of viral spillover. Improving disease surveillance in high-risk areas and scaling up research and development for traditional vaccines and therapeutics for humans and livestock are also key strategies.

Given the extremely high-risk and international nature of this work, and because the consequences are “potentially irreversible,” Lentzos says stakeholders must engage in dialogue on how this research is regulated, and Nuismer and Redwood agree that there is still a long way to go.

“You don’t need to be a Rhodes scholar to work out that people will be nervous about a disseminating viral vector. It’s a concept that will scare people,” says Redwood. “The way that I like to think about it is that it may never be used, but it’s better to have something in the cupboard that can be used and is mature if we need it. And to say, ‘Let’s just not do this research because it’s too dangerous,’ to me, that makes no sense at all.”

Next Post

Mental Health Crisis Looms in Russia as Sanctions Fuel Drug Shortages, Job Losses

Sasha, a 26-year-old animal behaviorist from Moscow, had seen a steady improvement in her mental health over the last three years.  Thanks to her passion for her job and rigorous micro-management of her medication, she was able to build a successful blog with a 27,000-strong audience and shake off a […]